Genenta Science S.p.A.

NasdaqCM GNTA

Genenta Science S.p.A. Capital Expenditure for the year ending December 31, 2023: USD -15.22 K

Genenta Science S.p.A. Capital Expenditure is USD -15.22 K for the year ending December 31, 2023, a 47.44% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Genenta Science S.p.A. Capital Expenditure for the year ending December 31, 2022 was USD -28.96 K, a -182.42% change year over year.
Genenta Science S.p.A. Capital Expenditure for the year ending December 31, 2021 was USD -10.26 K, a 59.78% change year over year.
Genenta Science S.p.A. Capital Expenditure for the year ending December 31, 2020 was USD -25.50 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: GNTA

Genenta Science S.p.A.

CEO	Mr. Pierluigi Paracchi
IPO Date	Dec. 15, 2021
Location	Italy
Headquarters	Via Olgettina No. 58
Employees	14
Sector	Healthcare
Industries Biotechnology

Description

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Key trends

Past 5 years